Genmab A/S
GNMSF
$241.84
-$3.16-1.29%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.38B | 3.23B | 3.12B | 2.89B | 2.76B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.38B | 3.23B | 3.12B | 2.89B | 2.76B |
| Cost of Revenue | 187.39M | 158.39M | 143.39M | 113.42M | 84.73M |
| Gross Profit | 3.19B | 3.07B | 2.98B | 2.77B | 2.67B |
| SG&A Expenses | 575.96M | 560.96M | 559.96M | 516.30M | 514.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.19B | 2.15B | 2.11B | 1.94B | 1.88B |
| Operating Income | 1.18B | 1.09B | 1.01B | 942.03M | 875.86M |
| Income Before Tax | 1.44B | 1.32B | 1.32B | 954.68M | 1.09B |
| Income Tax Expenses | 168.02M | 185.02M | 193.02M | 271.64M | 287.55M |
| Earnings from Continuing Operations | 1.27K | 1.13K | 1.13K | 683.04 | 803.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.27B | 1.13B | 1.13B | 683.04M | 803.76M |
| EBIT | 1.18B | 1.09B | 1.01B | 942.03M | 875.86M |
| EBITDA | 1.23B | 1.13B | 1.06B | 979.90M | 910.40M |
| EPS Basic | 20.09 | 17.80 | 17.70 | 10.60 | 12.37 |
| Normalized Basic EPS | 13.63 | 12.69 | 12.43 | 8.42 | 9.79 |
| EPS Diluted | 19.95 | 17.66 | 17.55 | 10.52 | 12.27 |
| Normalized Diluted EPS | 13.54 | 12.60 | 12.33 | 8.35 | 9.71 |
| Average Basic Shares Outstanding | 252.51M | 255.19M | 256.33M | 258.14M | 259.95M |
| Average Diluted Shares Outstanding | 253.99M | 256.85M | 258.22M | 260.13M | 262.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |